Cancer Family
Lymphocytic Neoplasm
CI-CAN-00000223Explore in graph →
HematologicNon-malignant3,036 active trials72 approved drugs345 evidence items
- NCIt
- C7065
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000223Explore in graph →
Clinical trials
12,949 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02905942 | PEG-rhG-CSF in Lymphoma Patients After Autologous Hematopoietic Stem Cell Transplantation | unknown | Phase 4 | 96 | Peking UniversityOTHER | 1 | Sep 19, 2016 | clinicaltrials |
| NCT02737085 | the Sequential Therapy of CD19-targeted and CD20-targeted CAR-T Cell Therapy for Diffuse Large B Cell Lymphoma(DLBCL) | unknown | Phase 1 / Phase 2 | 40 | Southwest Hospital, ChinaOTHER | 1 | Sep 7, 2016 | clinicaltrials |
| NCT02846584 | a Clinical Research of Sequential CAR-T Bridging HSCT in the Treatment of Relapse/Refractory B-cell Malignancies | unknown | Phase 2 | 100 | Southwest Hospital, ChinaOTHER | 1 | Sep 7, 2016 | clinicaltrials |
| NCT02881749 | Low Dose Total Skin Electron Beam Treatment (TSEBT) Followed by Maintenance Valchlor for Patients With Mycosis Fungoides | unknown | Phase 2 | 68 | Thomas Jefferson UniversityOTHER | 0 | Aug 30, 2016 | clinicaltrials |
| NCT02878278 | Differences Between Chidamide Taken Daily and Twice a Week in Therapeutic Effect，Pharmacokinetics, Pharmacodynamics and EB Virus Activation | unknown | Phase 2 | 24 | Huiqiang HuangOTHER | 0 | Aug 25, 2016 | clinicaltrials |
| NCT02856685 | A Study of Mitoxantrone Hydrochloride Liposome Infusion | unknown | Phase 1 / Phase 2 | 60 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Aug 22, 2016 | clinicaltrials |
| NCT02856997 | Chidamide With ICE Regimen for Relapsed/Refractory Peripheral T Cell Lymphoma | unknown | Phase 2 | 35 | Yuankai ShiOTHER | 0 | Aug 5, 2016 | clinicaltrials |
| NCT02456350 | Anti-CD19 Chimeric Antigen Receptor (CAR)-Transduced T Cell Therapy for Patients With B Cell Malignancies | unknown | Phase 1 | 36 | Shenzhen Second People's HospitalOTHER | 1 | Aug 3, 2016 | clinicaltrials |
| NCT02457650 | T Cell Receptor-transduced T Cells Targeting NY-ESO-1 for Treatment of Patients With NY-ESO-1- Expressing Malignancies | unknown | Phase 1 | 36 | Shenzhen Second People's HospitalOTHER | 1 | Aug 3, 2016 | clinicaltrials |
| NCT02544724 | NM-IL-12 (rHuIL-12) In Relapsed/Refractory Diffuse Large B- Cell Lymphoma (DLBCL) Undergoing Salvage Chemotherapy | unknown | Phase 2 | 12 | Neumedicines Inc.INDUSTRY | 0 | Aug 3, 2016 | clinicaltrials |
| NCT02766868 | Sequential Intensive Chemotherapy Followed by RIC for Refractory and Relapse ALL | unknown | Phase 2 | 20 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Aug 1, 2016 | clinicaltrials |
| NCT02851589 | Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma | unknown | Phase 1 / Phase 2 | 10 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Aug 1, 2016 | clinicaltrials |
| NCT01279902 | Abbreviated R-CHOP in Completely Excised Stage I or II DLBCL | unknown | Phase 2 | 32 | Asan Medical CenterOTHER | 1 | Jul 26, 2016 | clinicaltrials |
| NCT02184897 | Pharmacokinetic and Pharmacodynamic Study of Lenograstim for Hematopoietic Stem Cell Mobilization | unknown | N/A | 24 | Asan Medical CenterOTHER | 1 | Jul 26, 2016 | clinicaltrials |
| NCT02404571 | GDP in Frontline Chemotherapy for Patients With PTCL-NOS | unknown | Phase 2 | 28 | Chinese Academy of Medical SciencesOTHER | 1 | Jul 26, 2016 | clinicaltrials |
| NCT02842931 | R-Dose-adjusted (DA) - EPOCH-21 Versus R-modified Non-Hodgkin Lymphoma (NHL)-Berlin-Frankfurt-Munster (BFM)-90 Program (mNHL-BFM-90) and Autologous Stem Cells Transplantation (Auto-SCT) in DLBCL With Poor Prognosis | unknown | Phase 3 | 300 | National Research Center for Hematology, RussiaNETWORK | 1 | Jul 25, 2016 | clinicaltrials |
| NCT02836639 | BEB Conditioning Regimen for Autologous Stem-cell Transplantation(ASCT) in Non-Hodgkin's Lymphoma | unknown | Phase 2 | 20 | Pusan National University HospitalOTHER | 1 | Jul 19, 2016 | clinicaltrials |
| NCT02828774 | Peptide-drug-conjugates for Personalized, Targeted Therapy of Chronic Lymphocytic Leukemia | unknown | — | 30 | Assuta Medical CenterOTHER | 0 | Jul 12, 2016 | clinicaltrials |
| NCT02813837 | Chimeric Antigen Receptor T Cells (CART) Therapy in Refractory/Relapsed B Cell Hematologic Malignancies | unknown | N/A | 30 | Innovative Cellular Therapeutics Co., Ltd.OTHER | 1 | Jun 28, 2016 | clinicaltrials |
| NCT01671826 | Autologous Stem Cell Transplantation for Myeloma Patients Over 65 Years(LATMM) | unknown | — | 55 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Jun 24, 2016 | clinicaltrials |
| NCT02315118 | Pilot Study of Autologous T Lymphocytes With ADCC in Patients With CD20-Positive B-Cell Malignancies | unknown | Phase 1 / Phase 2 | 18 | National University Hospital, SingaporeOTHER | 1 | Jun 22, 2016 | clinicaltrials |
| NCT02779101 | Study on Pembrolizumab for Recurrent Primary Central Nervous System Lymphoma (PCNSL) | unknown | Phase 2 | 21 | Prof. Dr. Matthias PreusserOTHER | 1 | Jun 22, 2016 | clinicaltrials |
| NCT02808520 | Social Inequalities in the Participation and Activity in Children and Adolescents With Hodgkin-lymphoma | unknown | — | 700 | Martin-Luther-Universität Halle-WittenbergOTHER | 0 | Jun 21, 2016 | clinicaltrials |
| NCT02803840 | Low-dose Radiotherapy for Diffuse Large B-cell Lymphoma | unknown | Phase 2 | 25 | Centro di Riferimento Oncologico - AvianoOTHER | 1 | Jun 17, 2016 | clinicaltrials |
| NCT01991158 | GAD-M Regimen As First-Line Treatment in Untreated Extranodal NK/T Cell Lymphoma | unknown | Phase 2 | 30 | Sun Yat-sen UniversityOTHER | 1 | Jun 14, 2016 | clinicaltrials |
| NCT02797041 | Bortezomib as First Salvage Therapy for Myeloma Patients Previously Exposed to Bortezomib as Initial Treatment.(REBOUND) | unknown | — | 100 | IRCCS Centro di Riferimento Oncologico della BasilicataOTHER | 0 | Jun 14, 2016 | clinicaltrials |
| NCT02792491 | Phase II Prospective Trial of Addition of Rituximab to Reduced Dose CHOP Chemotherapy in DLBC L Patients Aged 65 Years and Over | unknown | Phase 2 | 57 | Pusan National University HospitalOTHER | 0 | Jun 9, 2016 | clinicaltrials |
| NCT02777736 | CNS Prophylaxis in Diffuse Large B-cell Lymphoma(CLSG-CNS-001) | unknown | Phase 3 | 500 | Czech Lymphoma Study GroupOTHER | 1 | Jun 6, 2016 | clinicaltrials |
| NCT02791217 | Identification of Hematological Malignancies and Therapy Predication Using microRNAs as a Diagnostic Tool | unknown | — | 100 | Assuta Medical CenterOTHER | 0 | Jun 6, 2016 | clinicaltrials |
| NCT01522872 | Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma | unknown | Phase 1 / Phase 2 | 98 | Threshold PharmaceuticalsINDUSTRY | 1 | Jun 2, 2016 | clinicaltrials |
| NCT01933711 | Rituximab Maintenance Therapy in Aggressive CD20 (Cluster of Differentiation Antigen 20) Positive Lymphoma and Mantle Cell Lymphoma | unknown | Phase 3 | 328 | University Hospital HeidelbergOTHER | 1 | May 13, 2016 | clinicaltrials |
| NCT02765620 | PERCIST Criteria for Response Evaluation With Solid Tumors | unknown | — | 150 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | May 6, 2016 | clinicaltrials |
| NCT02758925 | CyBeR Association in Relapsed/Refractory DLBCL(CyBeR-Lymph) | unknown | Phase 2 | 78 | University Hospital, CaenOTHER | 0 | May 4, 2016 | clinicaltrials |
| NCT02759822 | Haploidentical Hematopoietic Stem Cell Transplantation for Acute Leukemias | unknown | — | 30 | Leonardo Javier ArcuriOTHER_GOV | 1 | May 3, 2016 | clinicaltrials |
| NCT02753062 | Bendamustine Plus Subcutaneous Rituximab in Patients With Diffuse Large B-cell Lymphoma(PTLD) | unknown | Phase 2 | 22 | Asan Medical CenterOTHER | 1 | Apr 27, 2016 | clinicaltrials |
| NCT01079013 | Treosulfan-based Conditioning for Allogeneic Stem-cell Transplantation (SCT) in Lymphoid Malignancies | unknown | Phase 2 | 40 | Sheba Medical CenterOTHER_GOV | 1 | Apr 20, 2016 | clinicaltrials |
| NCT02080234 | Combine GELOX With Concurrent Radiation Therapy for Patients With Stage IE/IIE ENKTL | unknown | Phase 2 | 40 | Sun Yat-sen UniversityOTHER | 1 | Apr 20, 2016 | clinicaltrials |
| NCT02362165 | CyBorD vs. PAD in the Treatment of Newly Diagnosed Multiple Myeloma | unknown | Phase 3 | 236 | Sun Yat-sen UniversityOTHER | 1 | Apr 20, 2016 | clinicaltrials |
| NCT02507479 | Thiotepa-based Conditioning for Allogeneic Stem-cell Transplantation (SCT) in Lymphoid Malignancies | unknown | Phase 2 | 24 | Sheba Medical CenterOTHER_GOV | 1 | Apr 20, 2016 | clinicaltrials |
| NCT02240537 | Phase I Study of an Oncofetal Antigen Multi-Peptide Immunotherapy in Subjects With Hematologic Cancer(BBMPI03) | unknown | Phase 1 | 4 | Benovus Bio, Inc.INDUSTRY | 1 | Apr 19, 2016 | clinicaltrials |
| NCT02539472 | Early Diagnosis of Mycosis Fungoides(DIAPREMYF) | unknown | N/A | 620 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Apr 18, 2016 | clinicaltrials |
| NCT02733887 | MRI Compared to PET/CT for Staging and Treatment Response in Lymphoma | unknown | N/A | 66 | Guangxi Medical UniversityOTHER | 1 | Apr 12, 2016 | clinicaltrials |
| NCT02722733 | Randomized Trial of G-CSF Alone Versus Intermediate-dose Ara-C Plus G-CSF Mobilization in Hodgkin's Lymphoma or Non-Hodgkin's Lymphoma | unknown | Phase 3 | 90 | Maria Sklodowska-Curie National Research Institute of OncologyOTHER | 1 | Mar 30, 2016 | clinicaltrials |
| NCT02388581 | First-line Antibiotic Therapy for Early-stage HP(+) Gastric Pure DLBCL | unknown | Phase 2 | 30 | National Health Research Institutes, TaiwanOTHER | 1 | Mar 25, 2016 | clinicaltrials |
| NCT01541332 | Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Relapsed/Refractory Multiple Myeloma | unknown | Phase 1 / Phase 2 | 70 | OncotherapeuticsINDUSTRY | 1 | Mar 10, 2016 | clinicaltrials |
| NCT02413021 | The Effect of Deferasirox on Response Rate of Acute Leukemia Patients Not Treated by Standard Chemotherapy Regimens | unknown | Phase 1 | 40 | Isfahan University of Medical SciencesOTHER | 0 | Feb 25, 2016 | clinicaltrials |
| NCT01799083 | Lower Dose Decitabine Based Therapy in Patients With Refractory and/or Chemotherapy Resistant Solid Tumors or B Cell Lymphomas(CIK) | unknown | Phase 1 / Phase 2 | 100 | Han weidongOTHER | 1 | Jan 28, 2016 | clinicaltrials |
| NCT01864889 | Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by CART19(CART19) | unknown | N/A | 12 | Chinese PLA General HospitalOTHER | 1 | Jan 28, 2016 | clinicaltrials |
Data updated 23 days agoSource updated Sep 19, 2016source: clinicaltrials